References
- Pagano L, Caira M, Valentini CG, et al. Current therapeutic approaches to fungal infections in immunocompromised hemato- logical patients. Blood Rev 2010;24:51–61.
- Hammond SP, Marty FM, Bryar JM, et al. Invasive fungal disease in patients treated for newly diagnosed acute leukemia. Am J hematol 2010;85:695–69.
- Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495–503.
- Gomes MZ, Jiang Y, Mulanovich VE, et al. Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrob Agents Chemother 2014;58:2775–2780.
- Perfect JR, Hachem R, Wingard JR. Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. Clin Infect Dis 2014;59(Suppl 5):S352–355.
- De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821.
- Chakrabarti A, Chatterjee SS, Das A, et al. Invasive aspergillosis in developing countries. Med Mycol 2011;49(Suppl 1):S35–47.
- Lavaju P, Arya SK, Khanal B, et al. Demograhic pattern, clinical features and treatment outcome of patients with infective keratitis in the eastern region of Nepal. Nepal J Ophthalmol 2009;1: 101–106
- Joshi RR, Bhandary S, Khanal B, et al. Fungal maxillary sinusitis: a prospective study in a tertiary care hospital of eastern Nepal. Kathmandu Uni Med J 2007;5:195–198.
- Johansen HK, Gotzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2000;3:CD000969.
- Pascual B, Ayestaran A, Montoro JB, et al. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 1995;29:1197–11201
- Sundar S, Pandey K, Thakur CP, et al. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. PLoS Negl Trop Dis 2014;8:e3169.
- Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006;17:1306–1312.
- Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transpl 1999;23:163–168.
- Malik IA, Moid I, Aziz Z, et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998;105:478–483.
- Timmers GJ, Zweegman S, Simoons-Smit AM, et al. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transpl 2000;25: 879–884.
- Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008;31:135–141.